Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3786 - Transcriptomic stratification of breast carcinomas with double-equivocal HER2 status


10 Oct 2016


Poster display


Caterina Marchio


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


C. Marchio1, P. Dell'Orto2, L. Annaratone1, N. Rangel1, A. Özgüzer3, L. Verdun Di Cantogno4, A. Sapino3, G. Viale2

Author affiliations

  • 1 Department Of Medical Sciences, Università degli Studi di Torino, 10126 - Torino/IT
  • 2 Pathology, University of MIlan, European Institute of Oncology, 20141 - Milan/IT
  • 3 Pathology Unit, Istituto di Candiolo-IRCCS-Fondazione Piemontese per la Ricerca sul Cancro-Onlus, 10060 - Candiolo/IT
  • 4 Pathology Unit, Città della Saluta e della Scienza - Torino, 10126 - Torino/IT


Abstract 3786


The evaluation of HER2 overexpression and amplification in breast cancer (BC) provides a validated predictor of response to anti-HER2 agents. However, the algorithm based on immunohistochemistry (IHC) and in situ hybridization (ISH) still identifies a category of carcinomas that remain equivocal after ISH testing (“double equivocal” carcinomas). These carcinomas represent a real challenge for oncologists, who have to face the dilemma “to treat or not to treat”. The ASCO/CAP guidelines stress the need for data defining their biology and clinical behavior. Our aim was to stratify double-equivocal BCs by using transcriptomics.


We retrieved a series of 28 formalin fixed paraffin embedded double-equivocal BCs, i.e. showing HER2/CEP17 ratio 


All cases were estrogen receptor positive and 68% showed progesterone receptor expression in more than 20% of tumor cells. The large majority of double equivocal BCs were classified by Prosigna as pertaining to the Luminal B molecular subgroup (23/28, 82%); three cases (11%) were classified as Luminal A and two cases (7%) as HER2-enriched. These carcinomas frequently (23/28, 82%) showed a high risk of recurrence (ROR) even when the analysis was restricted to node negative BCs showing a tumor size


Double equivocal BCs preferentially pertain to the Luminal B rather than to the HER2-enriched molecular subgroup. Nevertheless, our data show that these luminal B carcinomas, even when node negative and of small tumor size, preferentially harbor a high risk of recurrence. This transcriptomic stratification may help in the treatment decision making of this controversial category of BC.

Clinical trial identification

Legal entity responsible for the study

University of Turin


Italian Association for Cancer Research


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings